Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma,…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q1 2026 Mar 2026 | $2.48B | +1.9% | $319.5M | $2.15 | +31.1% | 73.3% | 18.6% |
| Q4 2025 Dec 2025 | $2.28B | — | $-48.9M | $-0.33 | — | 78.3% | 16.9% |
| Q3 2025 Sep 2025 | $2.53B | — | $466.5M | $3.17 | — | 73.4% | 23.9% |
| Q2 2025 Jun 2025 | $2.65B | — | $634.8M | $4.33 | — | 77.1% | 32.2% |
| Q1 2025 Mar 2025 | $2.43B | — | $240.5M | $1.64 | — | 74.1% | 25.7% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Can Biogen’s revolutionary new Alzheimer’s treatments save the company’s valuation, or is the massive market sell-off a warning sign for investors? Maik Kemper Editor in Chief What does…